Jordan, represented by the Jordan Food and Drug Administration (JFDA), has officially become a member of the Pharmaceutical Inspection Cooperation Scheme (PIC/S), making it the second Arab country to join this global organization. The membership was granted after Jordan met all required standards and received approval from member states during the PIC/S meeting held in Hong Kong. This milestone reflects JFDA’s ongoing commitment to the highest standards of quality and pharmaceutical oversight.
اضافة اعلان
In a press statement, JFDA emphasized that this achievement is part of its strategic vision for regulatory excellence both regionally and internationally. The journey began in 2018 with the submission of the membership file, successfully passing the first phase by the end of 2020, which qualified the agency to apply for the second phase in early 2021. During this period, JFDA staff worked diligently to enhance regulatory systems and legislation, particularly within the Drug Directorate’s Pharmaceutical Inspection Department and the Drug Control Laboratory, to align inspection procedures with global pharmaceutical standards.
PIC/S is one of the leading international organizations in pharmaceutical oversight, currently comprising 56 regulatory authorities worldwide. The organization aims to harmonize standards and procedures in Good Manufacturing Practices (GMP), standardize global pharmaceutical inspections, implement monitoring and training programs for inspectors, and promote cooperation and knowledge exchange among national and regional regulatory bodies.
Membership in PIC/S enables JFDA to serve as an accredited reference authority for pharmaceutical inspections, enhancing the efficiency and quality of drug manufacturing in Jordan. It also facilitates drug exports by providing international recognition of Jordan’s GMP-compliant manufacturing practices, opening new markets for Jordanian pharmaceutical products.
Dr. Rana Abidat, Director-General of JFDA, highlighted that this membership reflects global confidence in Jordan’s capability to ensure the quality and safety of medicines. She noted that it supports the professional development of inspectors through participation in PIC/S training programs and the exchange of inspection reports and information among member states.
Dr. Abidat added that this development improves resource utilization, standardizes inspection procedures, and activates a rapid alert system among member countries to safeguard the quality and safety of pharmaceutical products worldwide. She also commended the efforts of JFDA staff and all contributors to achieving this international accreditation, expressing optimism for further accomplishments.
(Petra)
